Immunitas Therapeutics
BioTech/Drugs - Waltham, MA, US
Immunitas Therapeutics Employees
Immunitas Therapeutics Senior Management
Immunitas Therapeutics Details
Immunitas is an immuno-oncology therapeutics company advancing multiple programs to the clinic. Immunitas' programs are derived from a cross-functional, highly integrated, single cell genomics platform that enables rapid target identification and validation in parallel with antibody discovery and engineering. IMT-009, a first-in-class T & NK cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. The company was founded with leading scientists from Dana Farber, MGH, the Broad, and MIT. In 2019, Immunitas raised a $39M Series A from a strong syndicate of investors including the Longwood Fund, Hillhouse, NVF, Leaps by Bayer, and M Ventures.
Immunitas Therapeutics Technologies
E-commerce Platforms
Squarespace ECommerce
Email Providers
Mimecast
Fonts
Typekit
Other
Mobile Friendly